| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Fusion Protein:ASXL1-EIF2S2 |
Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: ASXL1-EIF2S2 | FusionPDB ID: 7292 | FusionGDB2.0 ID: 7292 | Hgene | Tgene | Gene symbol | ASXL1 | EIF2S2 | Gene ID | 171023 | 8894 |
| Gene name | ASXL transcriptional regulator 1 | eukaryotic translation initiation factor 2 subunit beta | |
| Synonyms | BOPS|MDS | EIF2|EIF2B|EIF2beta|PPP1R67|eIF-2-beta | |
| Cytomap | 20q11.21 | 20q11.22 | |
| Type of gene | protein-coding | protein-coding | |
| Description | polycomb group protein ASXL1additional sex combs like 1, transcriptional regulatoradditional sex combs like transcriptional regulator 1putative Polycomb group protein ASXL1 | eukaryotic translation initiation factor 2 subunit 2eukaryotic translation initiation factor 2, subunit 2 beta, 38kDaprotein phosphatase 1, regulatory subunit 67 | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | Q8IXJ9 | P20042 | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000470145, ENST00000306058, ENST00000375687, ENST00000375689, ENST00000542461, | ENST00000374980, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 16 X 10 X 8=1280 | 12 X 7 X 8=672 |
| # samples | 21 | 13 | |
| ** MAII score | log2(21/1280*10)=-2.60768257722124 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(13/672*10)=-2.36994960975031 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context (manual curation of fusion genes in FusionPDB) | PubMed: ASXL1 [Title/Abstract] AND EIF2S2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | ASXL1(30956926)-EIF2S2(32693351), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | ASXL1-EIF2S2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ASXL1-EIF2S2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ASXL1-EIF2S2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ASXL1-EIF2S2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | ASXL1 | GO:0035522 | monoubiquitinated histone H2A deubiquitination | 20436459 |
| Fusion gene breakpoints across ASXL1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across EIF2S2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Fusion Gene Sample Information |
| Fusion gene information from FusionGDB2.0. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | CESC | TCGA-DS-A7WH-01A | ASXL1 | chr20 | 30956926 | + | EIF2S2 | chr20 | 32693351 | - |
Top |
Fusion ORF Analysis |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000375687 | ASXL1 | chr20 | 30956926 | + | ENST00000374980 | EIF2S2 | chr20 | 32693351 | - | 3095 | 676 | 178 | 1662 | 494 |
| ENST00000542461 | ASXL1 | chr20 | 30956926 | + | ENST00000374980 | EIF2S2 | chr20 | 32693351 | - | 3085 | 666 | 171 | 1652 | 493 |
| ENST00000375689 | ASXL1 | chr20 | 30956926 | + | ENST00000374980 | EIF2S2 | chr20 | 32693351 | - | 2841 | 422 | 182 | 1408 | 408 |
| ENST00000306058 | ASXL1 | chr20 | 30956926 | + | ENST00000374980 | EIF2S2 | chr20 | 32693351 | - | 2656 | 237 | 0 | 1223 | 407 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000375687 | ENST00000374980 | ASXL1 | chr20 | 30956926 | + | EIF2S2 | chr20 | 32693351 | - | 0.000625566 | 0.99937445 |
| ENST00000542461 | ENST00000374980 | ASXL1 | chr20 | 30956926 | + | EIF2S2 | chr20 | 32693351 | - | 0.000736291 | 0.9992637 |
| ENST00000375689 | ENST00000374980 | ASXL1 | chr20 | 30956926 | + | EIF2S2 | chr20 | 32693351 | - | 0.000673236 | 0.9993268 |
| ENST00000306058 | ENST00000374980 | ASXL1 | chr20 | 30956926 | + | EIF2S2 | chr20 | 32693351 | - | 0.00057976 | 0.9994203 |
Top |
Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >7292_7292_1_ASXL1-EIF2S2_ASXL1_chr20_30956926_ENST00000306058_EIF2S2_chr20_32693351_ENST00000374980_length(amino acids)=407AA_BP=79 MGVVNFVFRASEDLQVLENYSDAPMTPKQILQVIEAEGLKEMSGTSPLACLNAMLHSNSRGGEGLFYKLPGRISLFTLKMIFDPTMSKKK KKKKKPFMLDEEGDTQTEETQPSETKEVEPEPTEDKDLEADEEDTRKKDASDDLDDLNFFNQKKKKKKTKKIFDIDEAEEGVKDLKIESD VQEPTEPEDDLDIMLGNKKKKKKNVKFPDEDEILEKDEALEDEDNKKDDGISFSNQTGPAWAGSERDYTYEELLNRVFNIMREKNPDMVA GEKRKFVMKPPQVVRVGTKKTSFVNFTDICKLLHRQPKHLLAFLLAELGTSGSIDGNNQLVIKGRFQQKQIENVLRRYIKEYVTCHTCRS -------------------------------------------------------------- >7292_7292_2_ASXL1-EIF2S2_ASXL1_chr20_30956926_ENST00000375687_EIF2S2_chr20_32693351_ENST00000374980_length(amino acids)=494AA_BP=166 MPPWATDAARARGAAAAPPPPPLSRQPVPACPPLLPGRTRDLARRRCHAPPPPPPPPQPRATAPARPARRSRVELPPPPGRRMKDKQKKK KERTWAEAARLVLENYSDAPMTPKQILQVIEAEGLKEMRSGTSPLACLNAMLHSNSRGGEGLFYKLPGRISLFTLKMIFDPTMSKKKKKK KKPFMLDEEGDTQTEETQPSETKEVEPEPTEDKDLEADEEDTRKKDASDDLDDLNFFNQKKKKKKTKKIFDIDEAEEGVKDLKIESDVQE PTEPEDDLDIMLGNKKKKKKNVKFPDEDEILEKDEALEDEDNKKDDGISFSNQTGPAWAGSERDYTYEELLNRVFNIMREKNPDMVAGEK RKFVMKPPQVVRVGTKKTSFVNFTDICKLLHRQPKHLLAFLLAELGTSGSIDGNNQLVIKGRFQQKQIENVLRRYIKEYVTCHTCRSPDT -------------------------------------------------------------- >7292_7292_3_ASXL1-EIF2S2_ASXL1_chr20_30956926_ENST00000375689_EIF2S2_chr20_32693351_ENST00000374980_length(amino acids)=408AA_BP=80 MGVVNFVFRASEDLQVLENYSDAPMTPKQILQVIEAEGLKEMRSGTSPLACLNAMLHSNSRGGEGLFYKLPGRISLFTLKMIFDPTMSKK KKKKKKPFMLDEEGDTQTEETQPSETKEVEPEPTEDKDLEADEEDTRKKDASDDLDDLNFFNQKKKKKKTKKIFDIDEAEEGVKDLKIES DVQEPTEPEDDLDIMLGNKKKKKKNVKFPDEDEILEKDEALEDEDNKKDDGISFSNQTGPAWAGSERDYTYEELLNRVFNIMREKNPDMV AGEKRKFVMKPPQVVRVGTKKTSFVNFTDICKLLHRQPKHLLAFLLAELGTSGSIDGNNQLVIKGRFQQKQIENVLRRYIKEYVTCHTCR -------------------------------------------------------------- >7292_7292_4_ASXL1-EIF2S2_ASXL1_chr20_30956926_ENST00000542461_EIF2S2_chr20_32693351_ENST00000374980_length(amino acids)=493AA_BP=165 MPPWATDAARARGAAAAPPPPPLSRQPVPACPPLLPGRTRDLARRRCHAPPPPPPPPQPRATAPARPARRSRVELPPPPGRRMKDKQKKK KERTWAEAARLVLENYSDAPMTPKQILQVIEAEGLKEMSGTSPLACLNAMLHSNSRGGEGLFYKLPGRISLFTLKMIFDPTMSKKKKKKK KPFMLDEEGDTQTEETQPSETKEVEPEPTEDKDLEADEEDTRKKDASDDLDDLNFFNQKKKKKKTKKIFDIDEAEEGVKDLKIESDVQEP TEPEDDLDIMLGNKKKKKKNVKFPDEDEILEKDEALEDEDNKKDDGISFSNQTGPAWAGSERDYTYEELLNRVFNIMREKNPDMVAGEKR KFVMKPPQVVRVGTKKTSFVNFTDICKLLHRQPKHLLAFLLAELGTSGSIDGNNQLVIKGRFQQKQIENVLRRYIKEYVTCHTCRSPDTI -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr20:30956926/chr20:32693351) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ASXL1 | EIF2S2 |
| FUNCTION: Probable Polycomb group (PcG) protein involved in transcriptional regulation mediated by ligand-bound nuclear hormone receptors, such as retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor gamma (PPARG) (PubMed:16606617). Acts as coactivator of RARA and RXRA through association with NCOA1 (PubMed:16606617). Acts as corepressor for PPARG and suppresses its adipocyte differentiation-inducing activity (By similarity). Non-catalytic component of the PR-DUB complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-119' (H2AK119ub1) (PubMed:20436459). Acts as a sensor of N(6)-methyladenosine methylation on DNA (m6A): recognizes and binds m6A DNA, leading to its ubiquitination and degradation by TRIP12, thereby inactivating the PR-DUB complex and regulating Polycomb silencing (PubMed:30982744). {ECO:0000250|UniProtKB:P59598, ECO:0000269|PubMed:16606617, ECO:0000269|PubMed:20436459, ECO:0000269|PubMed:30982744}. | FUNCTION: eIF-2 functions in the early steps of protein synthesis by forming a ternary complex with GTP and initiator tRNA. This complex binds to a 40S ribosomal subunit, followed by mRNA binding to form a 43S preinitiation complex. Junction of the 60S ribosomal subunit to form the 80S initiation complex is preceded by hydrolysis of the GTP bound to eIF-2 and release of an eIF-2-GDP binary complex. In order for eIF-2 to recycle and catalyze another round of initiation, the GDP bound to eIF-2 must exchange with GTP by way of a reaction catalyzed by eIF-2B. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | ASXL1 | chr20:30956926 | chr20:32693351 | ENST00000375687 | + | 4 | 13 | 2_9 | 84.0 | 1542.0 | Compositional bias | Note=Poly-Lys |
| Hgene | ASXL1 | chr20:30956926 | chr20:32693351 | ENST00000375687 | + | 4 | 13 | 11_86 | 84.0 | 1542.0 | Domain | HTH HARE-type |
| Tgene | EIF2S2 | chr20:30956926 | chr20:32693351 | ENST00000374980 | 0 | 9 | 124_129 | 5.0 | 334.0 | Compositional bias | Note=Poly-Lys | |
| Tgene | EIF2S2 | chr20:30956926 | chr20:32693351 | ENST00000374980 | 0 | 9 | 14_21 | 5.0 | 334.0 | Compositional bias | Note=Poly-Lys | |
| Tgene | EIF2S2 | chr20:30956926 | chr20:32693351 | ENST00000374980 | 0 | 9 | 79_87 | 5.0 | 334.0 | Compositional bias | Note=Poly-Lys | |
| Tgene | EIF2S2 | chr20:30956926 | chr20:32693351 | ENST00000374980 | 0 | 9 | 281_305 | 5.0 | 334.0 | Zinc finger | C4-type |
| - Not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | ASXL1 | chr20:30956926 | chr20:32693351 | ENST00000375687 | + | 4 | 13 | 1457_1460 | 84.0 | 1542.0 | Compositional bias | Note=Poly-Ser |
| Hgene | ASXL1 | chr20:30956926 | chr20:32693351 | ENST00000375687 | + | 4 | 13 | 199_209 | 84.0 | 1542.0 | Compositional bias | Note=Poly-Ser |
| Hgene | ASXL1 | chr20:30956926 | chr20:32693351 | ENST00000375687 | + | 4 | 13 | 641_684 | 84.0 | 1542.0 | Compositional bias | Note=Gly-rich |
| Hgene | ASXL1 | chr20:30956926 | chr20:32693351 | ENST00000375687 | + | 4 | 13 | 255_364 | 84.0 | 1542.0 | Domain | DEUBAD |
| Hgene | ASXL1 | chr20:30956926 | chr20:32693351 | ENST00000375687 | + | 4 | 13 | 160_164 | 84.0 | 1542.0 | Motif | Nuclear localization signal 1 |
| Hgene | ASXL1 | chr20:30956926 | chr20:32693351 | ENST00000375687 | + | 4 | 13 | 284_288 | 84.0 | 1542.0 | Motif | Note=LXXLL motif |
| Hgene | ASXL1 | chr20:30956926 | chr20:32693351 | ENST00000375687 | + | 4 | 13 | 409_413 | 84.0 | 1542.0 | Motif | Nuclear localization signal 2 |
| Hgene | ASXL1 | chr20:30956926 | chr20:32693351 | ENST00000375687 | + | 4 | 13 | 1503_1540 | 84.0 | 1542.0 | Zinc finger | Note=PHD-type%3B atypical |
Top |
Fusion Protein-Protein Interaction |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type from validated records (BIOGRID-3.4.160) |
| Gene | PPI interactors |
| Protein-protein interactors based on sequence similarity (STRING) |
| Gene | STRING network |
| ASXL1 | |
| EIF2S2 |
| - Retained interactions in fusion protein (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost interactions due to fusion (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| Hgene | ASXL1 | chr20:30956926 | chr20:32693351 | ENST00000375687 | + | 4 | 13 | 300_658 | 84.0 | 1542.0 | NCOA1 |
Top |
Related Drugs to ASXL1-EIF2S2 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to ASXL1-EIF2S2 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies